Wednesday, November 15, 2023
- 7:30AM-9:00AM
-
Abstract Number: L19
A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks
Late-Breaking Abstract Session- 7:30AM-9:00AM
-
Abstract Number: L15
AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography
Late-Breaking Abstract Session- 7:30AM-9:00AM
-
Abstract Number: L18
Immune-metabolic Heterogeneity and Clinical Implications in Primary Sjogren’s Syndrome Revealed by Molecular Classification of Salivary Glands
Late-Breaking Abstract Session- 7:30AM-9:00AM
-
Abstract Number: L17
Safety, Tolerability, and Exploratory Efficacy of Afimetoran, a TLR7/8 Inhibitor, in Patients with Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study
Late-Breaking Abstract Session- 7:30AM-9:00AM
-
Abstract Number: L20
Telitacicept, a Human Recombinant Fusion Protein Targeting and Neutralizing B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Rheumatoid Arthritis (RA) Patients with an Inadequate Response to Methotrexate (MTX): A Randomized, Double-Blind, Phase 3 Study
Late-Breaking Abstract Session- 7:30AM-9:00AM
-
Abstract Number: L16
Withdrawal of Immunosuppressant and Low-dose Steroids in IgG4-RD Patients with Stable Disease (WInS IgG4-RD): An Investigator-initiated, Multi-center, Open-label, Randomized Controlled Trial
Late-Breaking Abstract Session- 9:00AM-10:30AM
-
Abstract Number: 2575
Accurate Stratification of Cancer Risk in a Real-World Cohort Using the International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening
Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II- 9:00AM-10:30AM
-
Abstract Number: 2567
An Extended Interval Between mRNA COVID-19 Booster Vaccinations Is Associated with an Increased Humoral Immune Response in Patients with Inflammatory Rheumatic Diseases
Abstracts: Epidemiology & Public Health III- 9:00AM-10:30AM
-
Abstract Number: 2574
Are Patients Classified as IPAF More Likely to Also Meet SLE Criteria by 2019 EULAR/ACR Than by SLICC?: An Abstract
Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III- 9:00AM-10:30AM
-
Abstract Number: 2572
Autoantibody Profile of Autoimmune Driven Interstitial Lung Disease as Compared to Idiopathic Pulmonary Fibrosis and Association of Autoantibodies with Survival
Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III- 9:00AM-10:30AM
-
Abstract Number: 2563
Causal Associations Between Gut Microbiota and Rheumatic Diseases: A Mendelian Randomization Study
Abstracts: Epidemiology & Public Health III- 9:00AM-10:30AM
-
Abstract Number: 2566
Comparisons of the Risk of Serious Infections Associated with the Different Classes of Targeted Therapies Used in Psoriatic Arthritis Patients: A Nationwide Cohort Study from the French Health Insurance Database
Abstracts: Epidemiology & Public Health III- 9:00AM-10:30AM
-
Abstract Number: 2569
Efficacy and Safety of Therapeutic Interventions for the Treatment of Still’s Disease: A Systematic Review and Meta-analysis Informing the EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease
Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III- 9:00AM-10:30AM
-
Abstract Number: 2568
First Breakthrough COVID-19 Infection Following Two SARS-CoV-2 Vaccinations Among Primary Systemic Vasculitis Patients